What is claimed is:

1. A compound of having the structure:



wherein

one of R_1 or R_2 is –C(=O)OH and the other of R_1 or R_2 is –C(=O)OR_{13} or –C(=O)O-alkyl-R_{14},

wherein

R_{13} is aryl, and

R_{14} is aryl, and

R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each independently, H, -OR_{15} or halogen,

wherein R_{15} is H, $C_{1\text{-}10}$ alkyl,

wherein when one of R_1 or R_2 is –C(=O)OH and R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each H, then the other of R_1 or R_2 is other than –C(=O)OR_{13} where R_{13} is 1-naphthyl or 2-naphthyl, or –C(=O)O-alkyl-R_{14} where the alkyl is a branched C_2 alkyl and the R_{14} is phenyl,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein when one of R_1 or R_2 is –C(=O)OH and R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each H, then the other of R_1 or R_2 is other than –C(=O)OR_{13} where R_{13} is tolyl, 1-naphthyl or 2-

naphthyl, or –C(=O)O-alkyl-R_{14} where the alkyl is a branched C_2 alkyl and the R_{14} is phenyl.

3. The compound of claim 1, wherein when one of R_1 or R_2 is –C(=O)OH and the other of R_1 or R_2 is –C(=O)OR_{13} where R_{13} is 1-naphthyl or 2-naphthyl, then one of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} is other than –H; or

wherein when one of R_1 or R_2 is –C(=O)OH and the other of R_1 or R_2 is –C(=O)OR_{13} where R_{13} is 1-naphthyl or 2-naphthyl, then two of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than –H; or

wherein when one of R_1 or R_2 is –C(=O)OH and the other of R_1 or R_2 is –C(=O)OR_{13} where R_{13} is 1-naphthyl or 2-naphthyl, then four of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than –H.

4. The compound of claim 1,

wherein one of R_1 or R_2 is –C(=O)OR_{13},

wherein R_{13} is aryl; and

the other of R_1 or R_2 is –C(=O)OH.

5. The compound of claim 1,

wherein one of R_1 or R_2 is –C(=O)O-alkyl-R_{14},

wherein R_{14} is aryl; and

the other of R_1 or R_2 is –C(=O)OH.

6. The compound of claim 4, wherein the aryl is a substituted aryl, wherein the aryl is substituted with a halogen, heteroaryl, C_2-C_6 alkynyl, –O(alkyl), amide, aryl or hydroxyaryl.

7. The compound of claim 6, wherein the aryl is substituted with a F, Cl, Br, I, -NHC(O)CH_3, triazolyl, C_2 alkynyl, phenyl, *o*-hydroxyphenyl or –OCH_3.

8. The compound of claim 1,

wherein one of R_1 or R_2 is

 ,  ,  ,  ,  or  , and

the other of R_1 or R_2 is –C(=O)OH; or

wherein

one of R_1 or R_2 is

 ,  ,  ,  ,  or  , and

the other of R_1 or R_2 is –C(=O)OH; or

wherein

one of R1 or R2 is

 ,  ,  ,

 ,  , or  ; and

the other of R1 or R2 is –C(=O)OH.

9. The compound of claim 1, wherein R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each independently, -H, halogen or $-OR_{15}$,

wherein R_{15} is C_{1-10} alkyl.

10. The compound of claim 1, wherein two of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than –H; or wherein four of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than –H.

11. The compound of claim 1, wherein R_3, R_4, R_6, R_7, R_8, R_9, R_{11} and R_{12} are each –H; and R_5 and R_{10} are each halogen or $-OR_{15}$,

wherein R_{15} is C_{1-10} alkyl; or

wherein R_4, R_5, R_6, R_9, R_{10} and R_{11} are each –H; R_3 and R_{12} are each –H, halogen or $-OR_{15}$; and R_7 and R_8 are each halogen or $-OR_{15}$,

wherein R_{15} is C_{1-10} alkyl; or

wherein R_3, R_4, R_7, R_8, R_9 and R_{12} are each –H; and R_5, R_6, R_{10} and R_{11} are each halogen or $-OR_{15}$,

wherein R_{15} is C_{1-10} alkyl.

12. The compound of claim 1, wherein the compound is the (S,S) enantiomer.

13. The compound of claim 1, wherein the compound is the (R,R) enantiomer.

14. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

15. The composition of claim 14, wherein the composition comprises a mixture of enantiomers enriched in (S,S) enantiomer or a mixture of enantiomers enriched in (R,R) enantiomer.

16. The compound of claim 1, wherein R_{13} is substituted phenyl, unsubstituted naphthyl or unsubstituted indanyl,

wherein the substituted phenyl is substituted with phenyl,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1, wherein R_{13} is unsubstituted aryl,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 17,

wherein two of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than –H; or

wherein four of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than –H.

19. The compound of claim 1 having the structure:



,


,


,


,


,


or



,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

20. The compound of claim 18 having the structure:



,



or



,



or



,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

21. The compound of claim 5 having the structure:



,



,



,



,



,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.